Organism – Talk Bio

Seres Therapeutics Cuts 25% of Workforce Following FDA Feedback on Microbiome Therapy Trial

4 months ago talkbio0Tagged Biopharma, cash runway, Clinical Research, Feedback - system communication, layoffs, Microbiome, Microbiome SER-155, Seres, United States Food and Drug Administration

Seres Therapeutics; layoffs; microbiome; FDA feedback; SER-155; phase 2 trial; workforce reduction; biopharma; clinical studies; cash runway

VantAI and Halda Strike $1B+ AI-Driven Partnership on ‘Hold-and-Kill’ Drugs

5 months ago talkbio0Tagged Artificial Intelligence, cellular targeting, Chimera organism, Drug Discovery, Halda Therapeutics, hold-and-kill, Immunology, Induce (action), Neoplasms, Proximity, RIPTAC, target-effector pairs, VantAI

VantAI; Halda Therapeutics; RIPTAC drugs; hold-and-kill; AI drug discovery; target-effector pairs; oncology; immunology; regulated induced proximity targeting chimeras; $1 billion deal

Viome and Scripps Initiate AI-Powered At-Home RNA Test for Early Colon Cancer Risk Detection

6 months ago talkbio0Tagged AI-powered diagnostics, at-home colon cancer, Cancer Detection, Clinical Research, Colonic Polyps, Microbiome, RNA test, Screening for cancer, Scripps Research, Viome

Viome; Scripps Research; AI-powered diagnostics; RNA test; at-home colon cancer screening; colon polyps; clinical study; microbiome; early cancer detection

Vaccine-probiotic combo prevents, clears bacterial gut infections in mice in antibiotic alternative test

9 months ago talkbio0Tagged Antibiotics, House mice, Immune response, Probiotics, Vaccines

Antibiotics, Probiotics, House mice, Immune response, Vaccines

Nuvig Therapeutics Secures $161M Funding for Phase 2 Study in Autoimmune Diseases

1 year ago talkbio0Tagged Autoimmune Diseases, Chronic Idiopathic Demyelinating Polyneuropathy, CIDP, Fc Ab fragments, Nuvig, NVG-2089, Phase 2 Clinical Trials, Recombinants, synthetic manufacturing

Nuvig Therapeutics, autoimmune diseases, Phase 2 study, funding, NVG-2089, Chronic Idiopathic Demyelinating Polyneuropathy (CIDP), recombinant Fc Ab fragments, synthetic manufacturing.

Optimizing Expression of Multi-chain and Bispecific Antibodies: Strategies and Considerations

1 year ago talkbio0Tagged Antibodies, Antibodies, Bispecific, Cells, Chinese Hamster Ovary, CHO, Cultured Cell Line, expression vector, Metabolic Engineering, Optimization, production, Recombinants, Stable status

Bispecific Antibodies (bsAbs), Recombinant Antibody Production, Chinese Hamster Ovary (CHO) Cells, Expression Vector Optimization, Metabolic Engineering, Stable Cell Line Development